Physician profile
Deepak Sarwal
NPI 1235159559
$13,335.44
in general payments reported to CMS, 2019-2025
42 companies · $4,111 in 2025
The $4,111 reported for 2025 was more than what 86% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,962 · 2020: $296 · 2021: $990 · 2022: $1,168 · 2023: $1,462 · 2024: $3,346 · 2025: $4,111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,826 · Education: $92.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,826.03 |
| Education | $92.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,207.48 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $1,526.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $1,162.08 | 2021-2025 | |
| Medtronic Minimed, INC. | $965.95 | 2019-2020 | |
| Lilly USA, LLC | $962.50 | 2019-2025 | Mounjaro, Zepbound |
| Xeris Pharmaceuticals, INC. | $717.83 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $631.88 | 2024-2025 | Jardiance, Tradjenta, Synjardy |
| Janssen Pharmaceuticals, INC | $448.79 | 2019-2022 | |
| Dexcom, INC. | $403.17 | 2021-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $360.57 | 2021-2025 | Rexulti |
| Pfizer INC. | $359.58 | 2019-2023 | |
| Insulet Corporation | $346.40 | 2023-2025 | Omnipod |
| Corcept Therapeutics | $313.27 | 2023-2025 | Korlym |
| Tandem Diabetes Care, INC. | $277.45 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $276.79 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $268.13 | 2021-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $255.36 | 2024-2025 | Veozah |
| Medtronic, INC. | $241.85 | 2021-2025 | Minimed 780g |
| Astrazeneca Pharmaceuticals Lp | $218.28 | 2019-2024 | Farxiga |
| Cequr Corporation | $212.79 | 2023-2025 | Cequr Simplicity |
| Evoke Pharma, INC. | $162.51 | 2025 | |
| Amarin Pharma, INC. | $153.00 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $141.96 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $118.48 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Amphastar Pharmaceuticals, INC. | $84.10 | 2024-2025 | |
| Madrigal Pharmaceuticals | $74.56 | 2025 | Rezdiffra |
| Novartis Pharmaceuticals Corporation | $60.97 | 2022-2023 | |
| Biohaven Pharmaceuticals, INC. | $46.52 | 2021 | |
| Mannkind Corporation | $45.18 | 2023 | Afrezza |
| Sequel Med Tech, LLC | $42.87 | 2025 | Twiist |
| Exact Sciences Corporation | $36.64 | 2025 | Cologuard Collection Kit |
| Renalytix Ai, INC. | $34.53 | 2023-2024 | Kidneyintelx Blood Collection Convenience Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $31.17 | 2021 | |
| Zealand Pharma US, INC. | $30.71 | 2021 | |
| Lundbeck LLC | $27.89 | 2023-2025 | Vyepti, Rexulti |
| Eisai INC. | $26.53 | 2025 | |
| Bigfoot Biomedical INC | $17.42 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $17.07 | 2019 | |
| Allergan, INC. | $14.50 | 2019 | |
| Amgen INC. | $12.19 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Sarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.